AIMS: To determine whether the anticonvulsant carbamazepine (CBZ), a known CYP3A4 substrate, is also a substrate for the multidrug efflux transporter P-glycoprotein (Pgp). METHODS: The role of Pgp in the transport of CBZ was assessed in three systems: (a) in mdr1a/1b(-/-) and wild-type mice after administration of 2 mg kg-1 and 20 mg kg-1, which served as a model for brain penetration; (b) in Caco-2 cells, an in vitro model of the intestinal epithelium that is known to express high Pgp levels; and (c) by flow cytometry in lymphocytes using rhodamine 123, a fluorescent substrate for PgP. RESULTS: Brain penetration of both doses of CBZ at 1 h and 4 h was comparable in wild-type and mdr1a/1b(-/-) mice. Transport across the Caco-2 cell monolayer was Pgp-independent, and was not affected by the Pgp inhibitor PSC-833. CBZ had no effect on rhodamine 123 efflux from lymphocytes, in contrast to verapamil, which increased fluorescence intensity fivefold. CONCLUSION: CBZ is not a substrate for Pgp. Its efficacy is unlikely to be affected by Pgp over-expression in the brain. Furthermore, the interaction of CBZ with drugs that modulate both CYP3A4 and Pgp function such as verapamil is probably due to inhibition of CYP3A4 and not Pgp.
AIMS: To determine whether the anticonvulsant carbamazepine (CBZ), a known CYP3A4 substrate, is also a substrate for the multidrug efflux transporter P-glycoprotein (Pgp). METHODS: The role of Pgp in the transport of CBZ was assessed in three systems: (a) in mdr1a/1b(-/-) and wild-type mice after administration of 2 mg kg-1 and 20 mg kg-1, which served as a model for brain penetration; (b) in Caco-2 cells, an in vitro model of the intestinal epithelium that is known to express high Pgp levels; and (c) by flow cytometry in lymphocytes using rhodamine 123, a fluorescent substrate for PgP. RESULTS: Brain penetration of both doses of CBZ at 1 h and 4 h was comparable in wild-type and mdr1a/1b(-/-) mice. Transport across the Caco-2 cell monolayer was Pgp-independent, and was not affected by the Pgp inhibitor PSC-833. CBZ had no effect on rhodamine 123 efflux from lymphocytes, in contrast to verapamil, which increased fluorescence intensity fivefold. CONCLUSION:CBZ is not a substrate for Pgp. Its efficacy is unlikely to be affected by Pgp over-expression in the brain. Furthermore, the interaction of CBZ with drugs that modulate both CYP3A4 and Pgp function such as verapamil is probably due to inhibition of CYP3A4 and not Pgp.
Authors: M Pirmohamed; A Graham; P Roberts; D Smith; D Chadwick; A M Breckenridge; B K Park Journal: Br J Clin Pharmacol Date: 1991-12 Impact factor: 4.335
Authors: B M Kerr; K E Thummel; C J Wurden; S M Klein; D L Kroetz; F J Gonzalez; R H Levy Journal: Biochem Pharmacol Date: 1994-06-01 Impact factor: 5.858
Authors: Fahad I Al-Jenoobi; Mohd Aftab Alam; Khalid M Alkharfy; Saleh A Al-Suwayeh; Hesham M Korashy; Abdullah M Al-Mohizea; Muzaffar Iqbal; Abdul Ahad; Mohammad Raish Journal: Eur J Drug Metab Pharmacokinet Date: 2014-06 Impact factor: 2.441
Authors: Caroline F Thorn; Susan G Leckband; John Kelsoe; J Steven Leeder; Daniel J Müller; Teri E Klein; Russ B Altman Journal: Pharmacogenet Genomics Date: 2011-12 Impact factor: 2.089
Authors: Yogita Ghodke Puranik; Angela K Birnbaum; Susan E Marino; Ghada Ahmed; James C Cloyd; Rory P Remmel; Ilo E Leppik; Jatinder K Lamba Journal: Pharmacogenomics Date: 2013-01 Impact factor: 2.533
Authors: Laxmikant S Deshpande; Robert E Blair; Nisha Nagarkatti; Sompong Sombati; Billy R Martin; Robert J DeLorenzo Journal: Exp Neurol Date: 2007-01-09 Impact factor: 5.330
Authors: Andreas Johne; Elke S Perloff; Steffen Bauer; Jürgen Schmider; Ingrid Mai; Jürgen Brockmöller; Ivar Roots Journal: Eur J Clin Pharmacol Date: 2004-09-15 Impact factor: 2.953